NEPA ( Netupitant/Palonosetron) for the Prevention of Chemotherapy‐Induced Nausea and Vomiting ( CINV ) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial
Cancer Medicine · 2025
DOI: 10.1002/cam4.70549 ↗Kurz gefasst
Klinische Studie (Phase II) in der Zeitschrift Cancer Medicine, 2025. Verfasst von Rudolph M Navari und 1 weiteren Autor:innen. Beteiligte Einrichtung: World Health Organization, Mount Olive, Alabama, USA. Hauptthemen laut MEDLINE: Antiemetics, Antineoplastic Combined Chemotherapy Protocols, Nausea, Neoplasms. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: World Health Organization, Helsinn Therapeutics.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Although control of chemotherapy‐induced nausea and vomiting (CINV) is substantially improved with guideline‐directed antiemetic prophylaxis, breakthrough CINV remains a significant clinical patient problem. In subsequent cycles after breakthrough occurs, antiemetic guidelines recommend adding agents not used in the initial cycle. This study was designed to evaluate the use of NEPA (netupitant/palonosetron) plus dexamethasone with or without olanzapine for the prevention of CINV in the second cycle of chemotherapy for patients receiving highly (HEC) or moderately emetogenic chemotherapy (MEC) who developed breakthrough CINV in their first cycle despite guideline‐directed prophylactic antiemetics.
Methods
This was a Phase 2, single center, open‐label study. Patients received guideline‐recommended prophylactic antiemetics in Cycle 1 based on the chemotherapy emetogenicity. Patients who experienced breakthrough CINV in Cycle 1 received intravenous (IV) NEPA (Day 1) plus dexamethasone (Days 1–4) and olanzapine (Days 1–4) for HEC or IV NEPA (Day 1) plus dexamethasone (Days 1–4) for MEC in Cycle 2.
Results
Of the 227 patients enrolled in Cycle 1, 100 patients ( n = 37 HEC, 63 MEC) experienced breakthrough CINV and received the NEPA‐based treatments in Cycle 2. The complete response (no emesis/no rescue use) rates [95% confidence intervals] during the overall (0–120 h) phase were 76% [59%, 88%] and 79% [67%, 89%] in the HEC and MEC groups, respectively.
Conclusion
These results show that NEPA with or without olanzapine is an effective approach for CINV prevention for patients receiving HEC or MEC who develop breakthrough CINV after their first course of chemotherapy. The results support the antiemetic guideline recommendations. Trial Registration clinicaltrials.gov identifier: NCT06065722
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- World Health Organization, Mount Olive, Alabama, USA.
- RIDE2Med Foundation, Milan, Italy.
ORCID-Profile: Rudolph M Navari
Förderung
- World Health Organization
- Helsinn Therapeutics
Zitieren
APA
Navari, R. M., & Bonizzoni, E. (2025). NEPA ( Netupitant/Palonosetron) for the Prevention of Chemotherapy‐Induced Nausea and Vomiting ( CINV ) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Medicine. https://doi.org/10.1002/cam4.70549
Vancouver
Navari RM, Bonizzoni E. NEPA ( Netupitant/Palonosetron) for the Prevention of Chemotherapy‐Induced Nausea and Vomiting ( CINV ) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial. Cancer Medicine. 2025. doi:10.1002/cam4.70549
BibTeX
@article{Navari2025,
author = {Navari, Rudolph M and Bonizzoni, Erminio},
title = {NEPA ( Netupitant/Palonosetron) for the Prevention of Chemotherapy‐Induced Nausea and Vomiting ( CINV ) in Patients Receiving Highly or Moderately Emetogenic Chemotherapy Who Experienced Breakthrough CINV in Cycle 1 of Chemotherapy: A Phase II Clinical Trial},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.70549}
}
EUVIMED